Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 8/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310937 | 0.88 | CYP4A11 (0.47) | CYP4A11CYP4F2CA2SPHK1LMNA | |
| SCHEMBL5689956 | 0.85 | CA2 (0.52) | CYP4A11CYP4F2CA2 | |
| SCHEMBL28326928 | 0.84 | TSHR (0.43) | CA2GLSL3MBTL1 | |
| SCHEMBL242504 | 0.82 | CA2 (0.61) | CYP4A11CYP4F2CA2LMNA | |
| SCHEMBL27496644 | 0.81 | ESR1 (0.55) | CA2SPHK1LMNA | |
| SCHEMBL5323615 | 0.80 | SPHK1 (0.50) | CYP4A11CYP4F2CA2SPHK1LMNA | |
| SCHEMBL23837668 | 0.79 | CA2 (0.63) | CYP4A11CYP4F2CA2LMNA | |
| SCHEMBL31512262 | 0.79 | CA2 (0.63) | CYP4A11CYP4F2CA2LMNA | |
| SCHEMBL9670730 | 0.79 | CA2 (0.63) | CYP4A11CYP4F2CA2LMNA | |
| SCHEMBL3424786 | 0.79 | CA2 (0.63) | CYP4A11CYP4F2CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007095756-A1 | NOVEL CENTRAL-NERVOUS SYSTEM ACTING COMPOUNDS AND METHODS FOR THE TREATMENT OF CNS DISORDERS | CLERA INC. (CA) | 2007-08-30 | — | — | WO | disclosed |